Visit AtriplaAndMe.com
TAKING CARE OF
For adults with HIV-1,
WITH THE STRENGTH OF
Undetectable viral load is a goal, and ATRIPLA has the power to help get you there. In a clinical trial: • ATRIPLA has been proven to LOWER VIRAL LOAD to undetectable* in approximately 8 out of 10 adult patients new to therapy through 48 weeks compared with approximately 7 out of 10 adult patients in the comparator group† • ATRIPLA has been proven to LOWER VIRAL LOAD to undetectable* through 3 years in approximately 7 out of 10 adult patients new to therapy compared with approximately 6 out of 10 adult patients in the comparator group†
SELECTED IMPORTANT SAFETY INFORMATION What is the most important information I should know about ATRIPLA? n If you also have hepatitis B virus (HBV) infection and you stop taking ATRIPLA, you may get a “flare-up” of your hepatitis. A “flare-up” is when the disease suddenly returns in a worse way than before. Patients with HBV who stop taking ATRIPLA need close medical follow-up for several months to check for hepatitis that could be getting worse. ATRIPLA is not approved for the treatment of HBV, so you need to discuss your HBV therapy with your healthcare provider Please see additional Important Safety Information below. IMPORTANT SAFETY INFORMATION (continued) What important information should I know about taking other medicines with ATRIPLA? ATRIPLA may change the effect of other medicines, including the ones for HIV-1, and may cause serious side effects. Your healthcare provider may change your other medicines or change their doses. MEDICINES YOU SHOULD NOT TAKE WITH ATRIPLA n ATRIPLA should not be taken with: Combivir® (lamivudine/zidovudine), COMPLERA® (emtricitabine/rilpivirine/tenofovir disoproxil fumarate), DESCOVY® (emtricitabine/tenofovir alafenamide), EMTRIVA® (emtricitabine), Epivir® or Epivir-HBV® (lamivudine), Epzicom® (abacavir sulfate/lamivudine), GENVOYA® (elvitegravir/ cobicistat/emtricitabine/tenofovir alafenamide), ODEFSEY® (emtricitabine/rilpivirine/tenofovir alafenamide), STRIBILD® (elvitegravir/cobicistat/emtricitabine/tenofovir DF), Trizivir® (abacavir sulfate/lamivudine/zidovudine), TRUVADA® (emtricitabine/tenofovir DF), VEMLIDY® (tenofovir alafenamide), or VIREAD® (tenofovir DF). ATRIPLA should not be used with SUSTIVA® (efavirenz) unless recommended by your healthcare provider. n Vfend® (voriconazole) should not be taken with ATRIPLA since it may lose its effect or may increase the chance of having side effects from ATRIPLA. n ATRIPLA should not be used with HEPSERA® (adefovir dipivoxil).
These are not all the medicines that may cause problems if you take ATRIPLA. Tell your healthcare provider about all prescription and nonprescription medicines, vitamins, or herbal supplements you are taking or plan to take. What are the possible side effects of ATRIPLA? ATRIPLA may cause the following additional serious side effects n Too much lactic acid in your blood (lactic acidosis). This is a serious but rare medical emergency. Tell your healthcare provider right away if you get these symptoms: weakness or being more tired than usual, unusual muscle pain, being short of breath or fast breathing, stomach pain with nausea and vomiting, cold or blue hands and feet, feel dizzy or lightheaded, or a fast or abnormal heartbeat. n Severe liver problems. In rare cases, severe liver problems can happen that can lead to death. Tell your healthcare provider right away if you get these symptoms: skin or the white part of your eyes turns yellow, dark “tea-colored” urine, light-colored stools, loss of appetite for several days or longer, nausea, or stomach-area pain. Please see Important Safety Information continued on the following pages.
* In the above clinical trial, undetectable was defined as a viral load fewer than 400 copies/mL. Ask your doctor about your individual results. † In this study, 511 adult patients new to therapy received either the meds in ATRIPLA each taken once daily or Combivir® (lamivudine/zidovudine) twice daily + SUSTIVA® (efavirenz) once daily. ‡ Symphony Health Solutions, PatientSource APLD and Source® PHAST Prescription Monthly, counts are cumulative and equivalized. January 2007–December 2015.